Method for improving neuroplasticity

A method of treating one or more symptoms selected from depressive symptoms, anhedonia, loss of interest, avolition, diminished emotional expression, inability to feel, amotivation, apathy, slow thinking, psychomotor retardation, lassitude, or any combination of any of the foregoing in a human patient suffering from post-traumatic stress disorder, bipolar depression, substance use disorder or schizophrenia, where the patient has (a) objectively determined cognitive impairment or poor cognition, (b) objectively determined impaired learning and/or memory, (c) an electroencephalogram (EEG) exhibiting (i) a low aperiodic exponent, (ii) a high power in the low gamma range, (iii) a low power in the alpha frequency, (iv) low power at the centro-parietal electrodes in the theta frequencies, (v) low power at the centro-parietal electrodes in the alpha frequencies, (vi) low power at the frontal electrodes in the alpha frequencies, (vii) high aperiodic exponent at one or more posterior electrodes, or (viii) any combination of any of the foregoing, or (d) any combination of any of the foregoing, the method comprising administering to the patient an effective amount of a therapeutic agent, wherein the therapeutic agent is selected from (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, and (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound).